IBD

GI Issues in Kids With COVID-19 MIS-C May Muddy Diagnosis

— Pediatric multisystem inflammatory syndrome symptoms could mimic less toxic GI infections, IBD Children and adolescents with COVID-19 who developed multisystem inflammatory syndrome (MIS-C) often exhibited marked gastrointestinal (GI) manifestations, sometimes confounding diagnosis by mimicking GI infections or inflammatory bowel disease (IBD), according to a recent case series. In a chart review of 44 pediatric patients (ages 7 months to 20 years, ...

Read More »

New study sheds light on IBD patients with COVID-19

In an upcoming study to be published in Gastroenterology, researchers at the Icahn School of Medicine at Mount Sinai and the University of North Carolina School of Medicine report on the clinical course of COVID-19 and risk factors for adverse outcomes in a large cohort of patients with IBD collected through an international registry. When the COVID-19 epidemic started to unfold ...

Read More »

Are we using biologic therapy properly?

The introduction of infliximab (Remicade), the first biologic therapy approved for the treatment of inflammatory bowel diseases (IBD), did not result in lower rates of hospitalizations or intestinal surgeries among patients living with IBD in Ontario, according to a study published by authors from several Canadian hospitals and ICES in the journal Gut. The authors studied trends in hospitalizations, surgeries and ...

Read More »

Sinister blastocystis: a clandestine killer of good bacteria revealed

Since most of the microbes in our gut are bacteria, they tend to hog much of the microbiome research limelight. But, lurking amongst the bacteria are other microbes such as single-cell eukaryotes (SCE) and viruses, which have been largely ignored until now. If doctors and scientists think of Blastocystis (one the most common gut SCEs) at all, they often regard it as ...

Read More »

Study to compare the effectiveness of biologic or small molecule therapies in IBD receives funding

Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel diseases (IBD), which may affect as many as 3 million Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of ...

Read More »